Increasing the permeability of Escherichia coli using MAC13243 by Muheim, Claudio et al.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
General rights 
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners 
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. 
 
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research. 
• You may not further distribute the material or use it for any profit-making activity or commercial gain 
• You may freely distribute the URL identifying the publication in the public portal  
 
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately 
and investigate your claim. 
   
 
Downloaded from orbit.dtu.dk on: Jan 01, 2018
Increasing the permeability of Escherichia coli using MAC13243
Muheim, Claudio; Götzke, Hansjörg; Eriksson, Anna U.; Lindberg, Stina; Lauritsen, Ida; Nørholm,
Morten; Daley, Daniel O.
Published in:
Scientific Reports
Link to article, DOI:
10.1038/s41598-017-17772-6
Publication date:
2017
Document Version
Publisher's PDF, also known as Version of record
Link back to DTU Orbit
Citation (APA):
Muheim, C., Götzke, H., Eriksson, A. U., Lindberg, S., Lauritsen, I., Nørholm, M., & Daley, D. O. (2017).
Increasing the permeability of Escherichia coli using MAC13243. Scientific Reports, 7, [17629]. DOI:
10.1038/s41598-017-17772-6
1SCieNTiFiC REPORTS | 7: 17629  | DOI:10.1038/s41598-017-17772-6
www.nature.com/scientificreports
Increasing the permeability of 
Escherichia coli using MAC13243
Claudio Muheim1, Hansjörg Götzke1, Anna U. Eriksson2, Stina Lindberg2, Ida Lauritsen  3, 
Morten H. H. Nørholm  3 & Daniel O. Daley1
The outer membrane of gram-negative bacteria is a permeability barrier that prevents the efficient 
uptake of molecules with large scaffolds. As a consequence, a number of antibiotic classes are 
ineffective against gram-negative strains. Herein we carried out a high throughput screen for 
small molecules that make the outer membrane of Escherichia coli more permeable. We identified 
MAC13243, an inhibitor of the periplasmic chaperone LolA that traffics lipoproteins from the inner 
to the outer membrane. We observed that cells were (1) more permeable to the fluorescent probe 
1-N-phenylnapthylamine, and (2) more susceptible to large-scaffold antibiotics when sub-inhibitory 
concentrations of MAC13243 were used. To exclude the possibility that the permeability was caused by 
an off-target effect, we genetically reconstructed the MAC13243-phenotype by depleting LolA levels 
using the CRISPRi system.
A distinguishing feature of gram-negative bacteria is their outer membrane, which under normal physiological 
conditions is an asymmetric bilayer that contains mainly lipopolysaccharides (LPS) in the outer leaflet and phos-
pholipids in the inner leaflet1–3. This membrane is essentially an impermeable barrier that separates and protects 
the cell from the extra-cellular mileu. ß-barrel porins embedded in the outer membrane maintain cellular home-
ostasis by selecting the chemistry that enters and leaves the cell. It is generally accepted that ß-barrel porins allow, 
by passive diffusion, the passage of hydrophilic molecules that are less than 600 Da4–6. Molecular shape, flexibility 
and the presence of an ionisable nitrogen group are also important for diffusion through porins7. These exclusion 
limits enable the uptake of essential nutrients and ions, as well as those antibiotics with small molecular scaffolds. 
Antibiotics with larger and less favourable scaffolds cannot effectively cross the outer membrane (Fig. 1a). These 
large-scaffold antibiotics can, in some instances, diffuse through the LPS layer, but the process is inefficient and 
they are therefore considered ineffective against gram-negative bacteria8–10. Examples of large-scaffold antibiotics 
from four different antibiotic classes are shown in Fig. 1b.
Large-scaffold antibiotics are taken up more efficiently when the biogenesis of the cell envelope is perturbed. 
For example, in strains with genetic mutations that affect protein trafficking and folding in the cell envelope, or 
lipopolysaccharide biosynthesis11–14. A number of small molecules that inhibit the biogenesis of the cell envelope 
have been discovered (see15–24 for examples). But to our knowledge, only a few of these have been shown to poten-
tiate large-scaffold antibiotics: (1) polymyxins are cationic polypeptide antibiotics that disrupt the LPS layer15,24,25, 
(2) loperamide is an anti-diarrhoeal drug (target unknown) that dissipates the inner membrane potential17, (3) 
A22 is an inhibitor of the actin homologue MreB23. In this study we set out to discover new lead molecules 
that could be used to make the outer membrane of gram-negative bacteria more permeable to large-scaffold 
antibiotics.
Results
A high throughput screen for molecules that make E. coli susceptible to vancomycin. We ini-
tially carried out a high throughput screen to identify small molecules that make Escherichia coli more susceptible 
to vancomycin. Vancomycin is a glycopeptide antibiotic that exceeds the exclusion limit of ß-barrel porins and 
therefore cannot pass the outer membrane. However E. coli is susceptible to vancomycin when proteins involved 
in cell envelope biogenesis are inhibited; For example, a strain lacking the periplasmic chaperone SurA has a 
compromised outer membrane and is susceptible to much lower concentrations of vancomycin than a wild type 
(WT) strain12. Our screen was performed by monitoring the growth of E. coli MC4100 in a 96-well format, in the 
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presence of a sub-lethal concentration of vancomycin and 28,000 small molecules. We reasoned that if a small 
molecule increased the permeability of the outer membrane, vancomycin would gain access to the periplasm 
and cell growth would be inhibited (Fig. 2a). The screening conditions we selected were deemed to be robust as 
we observed a visible growth difference when the WT MC4100 and the vancomycin sensitive ∆surA strain were 
incubated in the presence of vancomycin at 1/3 the Minimal Inhibitory Concentration (MIC) (Z-score of 0.89; 
Fig. 2b). The primary screen was initially carried out with 17,500 small molecules from a diverse set of com-
pounds (ChemBridge) at 12.5 µM and in the presence of 100 µg mL−1 of vancomycin (1/5 MIC). As this did not 
yield any significant hits (data not shown) a second screen was carried out. In the second screen 10,500 small mol-
ecules were screened from the CBCS primary screening set at 10 µM in presence of 150 µg mL−1 of vancomycin 
(1/3 MIC). This second screen indicated that 124 small molecules inhibited the growth of MC4100 by more than 
30% relative to a DMSO control (red data points, Fig. 2c). Roughly half of these molecules exhibited antimicrobial 
activity in the absence of vancomycin and they were not considered further. Only 12 of the 124 small molecules 
inhibited cell growth in a vancomycin- and dose-dependent manner (Supplementary Figure 1). Six of these mol-
ecules were from antibiotic classes that were previously known to function synergistically with vancomycin in 
gram-negative bacteria23,26–28, and this category served as positive controls for the screen (1–6 Fig. 2d). The other 
six molecules were not previously known to work in combination with vancomycin and they were chosen for 
follow up experiments (7–12 Fig. 2d). This group included three nucleoside analogues (5-ethynyl-2′-deoxyuri-
dine, zebularine, floxuridine), two molecules that were annotated as antibiotics (carbadox, streptozotocin) and an 
inhibitor of the periplasmic chaperone LolA (MAC13243)7.
MAC13243 permeabilises the outer membrane of E. coli. We used the fluorescent probe 
1-N-phenylnapthylamine (NPN) to determine if the molecules identified in the screen were causing the outer 
membrane of E. coli to be more permeable. NPN is a small molecule (219 Da) that cannot effectively cross the 
outer membrane. It is weakly fluorescent in aqueous solution but fluoresces strongly when it binds to phospho-
lipids. This property can be exploited to probe the permeability of the outer membrane29,30: WT cells are weakly 
fluorescent since NPN is not effectively taken up, but strains with a compromised outer membrane are fluorescent 
since NPN can access the periplasmic space and the phospholipids of the inner and outer membranes (Fig. 3a). 
When we carried out NPN uptake assays in cells treated with a sub-lethal concentration of floxuridine, carba-
dox, streptozotocin and MAC13243, we observed that only cells treated with MAC13243 became fluorescent 
(Fig. 3b). We did not test 5-ethynyl-2′-deoxyuridine and zebularine since they were deemed to be analogues of 
floxuridine (Fig. 2d). The amount of fluorescence observed in cells treated with MAC13243 was 15x higher than 
the DMSO control (Fig. 3b) and was concentration dependent (Fig. 3c). To gauge how permeable the cells treated 
with MAC13243 had become, we compared the NPN fluorescence values to those seen in cells treated with a 
sub-inhibitory concentration of colistin, a polymyxin antibiotic that disrupts the LPS layer15,24. We observed that 
MAC13243-treated cells were more permeable than colistin-treated cells (Fig. 3c vs d). We also compared the 
NPN fluorescence values of MAC13243-treated cells to strains that were known to be more permeable. This com-
parison included a deep-rough strain that lacked a glycosyltransferase required for LPS synthesis (∆waaG)12,31 
and a strain carrying a deletion in a protein involved in LPS trafficking (lptD4213)32. These data indicated that 
cells treated with a sub-lethal concentration of MAC13243 were more permeable to NPN than the ∆waaG strain, 
and less permeable than the lptD4213 strain (Fig. 3e). Taken together these data indicate that a sub-lethal con-
centration of MAC13243 causes the outer membrane of E. coli to be more permeable to NPN. The molecular 
reason why compounds 7–11 made cells more susceptible to vancomycin in the original screen remains to be 
determined.
Figure 1. Schematic illustration of antibiotic uptake in E. coli. (a) Antibiotics less than 600 Da (herein called 
small-scaffold antibiotics) can generally permeate through non-specific outer membrane porins and gain 
access to the periplasm. Antibiotics larger than 600 Da (herein called large-scaffold antibiotics) exceed the 
size exclusion limit of outer membrane porins. These antibiotics can presumably diffuse through the outer 
membrane but the process is inefficient. Once in the periplasm both small- and large-scaffold antibiotics can, 
in principle, diffuse across the inner membrane or can be inadvertently taken up by membrane embedded 
transporters. (b) Chemical structures of four large-scaffold antibiotics from different classes.
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MAC13243 sensitises E. coli to large-scaffold antibiotics. To determine if the permeability observed 
in MAC13243-treated cells could be exploited to increase the uptake of large-scaffold antibiotics, we monitored 
cell growth in the presence of sub-lethal concentrations of vancomycin, rifampicin, erythromycin or novobiocin 
(Fig. 1b). In these experiments the assay conditions used were similar to those used in the original screen, except 
that antibiotics were used at ½ MIC. We observed that growth of MC4100 was only slightly perturbed when 
10 µM MAC13243 was present, moderately perturbed when the large-scaffold antibiotics were present at ½ MIC, 
and severely perturbed when both MAC13243 and large-scaffold antibiotics were present (Fig. 4a). The most 
likely explanation for these data is that 10 µM MAC13243 increased the permeability of the outer membrane and 
allowed the large-scaffold antibiotics to enter more efficiently.
To quantify how efficiently MAC13243 was working with the large-scaffold antibiotics we carried out cheq-
uerboard assays, which are a commonly used methodology to determine if two drugs work synergistically. In 
the chequerboard assays the assay conditions were slightly different (see methods) and growth inhibition was 
Figure 2. A high-throughput screen to identify small molecules that make E. coli more permeable. (a) An 
aliquot of E. coli MC4100 was seeded into individual wells of a 96-well microtiter plate in the presence of a sub 
MIC of vancomycin and small molecules. The plates were incubated for 5 h at 37 °C and cell growth (OD600) 
was compared to a DMSO control. (b) Growth curves of WT strain and a strain lacking the periplasmic 
chaperone SurA (ΔsurA) in the presence or absence of 150 μg mL−1 vancomycin (~1/3 MIC). The experiment 
indicates that growth of the WT strain is unaffected by a sub-lethal concentration of vancomycin, but growth 
of the ΔsurA is severely compromised. (c) Optical density readings of WT cells grown in the presence of 
150 μg mL−1 vancomycin (~1/3 MIC) and 10 μM of each small molecule from the LCBKI library. 124 small 
molecules (red dots) inhibited growth more than 30% compared to the growth control (dark green dots). 
Sterility controls are illustrated by blue dots and small molecules that did not inhibit cell growth by more than 
30% are illustrated as light green dots. (d) Chemical structures of 12 small molecules that inhibited cell growth 
in a vancomycin- and dose-dependent manner. 1–6 were from antibiotic classes that were previously known 
to function synergistically with vancomycin in gram-negative bacteria, and this category served as positive 
controls for the screen. 7–12 were not previously known to work in combination with vancomycin and they 
were chosen for follow up experiments.
www.nature.com/scientificreports/
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Figure 3. A sub-lethal concentration of MAC13243 makes the outer membrane of E. coli more permeable. (a) 
The NPN dye can be used to monitor the integrity of the outer membrane. NPN is excluded from WT cells but 
penetrates into cells with a compromised outer membrane where it binds to the phospholipid layer, resulting in 
prominent fluorescence. (b) E. coli MC4100 grown in M9 media were exposed to different small molecules (½ 
MIC), and the permeability of the outer membrane was assessed by measuring the fluorescence of NPN. MICs 
were determined to be 1 μg mL−1 for carbadox, 256 μg mL−1 for streptozotocin, 0.002 μg mL−1 for floxuridine 
and 256 μg mL−1 for MAC13243. Fluorescence values were compared to cells treated with a solvent control. 
Note that we did not test all small molecules in the NPN uptake assay, but focussed on those that were readily 
available and that were representative of a class. For example, floxuridine (9) was deemed to be representative 
of the nucleoside analogues (7, 8). (c) E. coli MC4100 were grown in M9 media then exposed to different 
concentrations of MAC13234 (MIC = 256 μg mL−1) and NPN uptake was monitored (left panel). The increase 
in fluorescence was deemed to be due to increased permeability of the outer membrane, not cell lysis, since the 
amount of MAC13243 used did not affect cell viability (right panel). In these experiments cell aliquots were 
harvested after the NPN uptake assays, 10-fold serially diluted and spotted on LB agar. All data (mean ± SD) are 
from four experiments. ****p < 0.0001 (unpaired t-test.). (d) As for panel c except that E. coli MC4100 were 
exposed to different concentrations of colistin (MIC = 1 μg mL−1). (e) As for panel c except that the permeability 
of different E. coli strains was assessed.
www.nature.com/scientificreports/
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evaluated in the presence of serial dilutions of MAC13243 and the large-scaffold antibiotics. The data were then 
used to calculate a Fractional Inhibitory Concentration Index (FICI). Following community guidelines the com-
binations were deemed to work synergistically if the FICI was ≤ 0.533. Using this mathematical assessment we 
observed that MAC13243 worked synergistically with erythromycin and novobiocin but not with vancomycin 
or rifampicin (Fig. 4b). MAC13243 did not work synergistically with the large-scaffold antibiotics when we car-
ried out chequerboard assays with two clinical isolates, E. coli O139 and O141 (data not shown). However it did 
increase the permeability of these strains to the NPN dye (Supplementary Figure 2). Taken together, these data 
indicate that MAC13243 is a promising lead molecule that can increase the efficacy of large-scaffold antibiotics, 
but that the molecular scaffold will need to be optimised if it is to be used as a potentiator.
How does MAC13243 affect outer membrane permeability? MAC13243 is an inhibitor of LolA21, 
the periplasmic chaperone that traffics lipoproteins from the inner membrane to the outer membrane13,34. It was 
initially touted as a promising antibiotic lead because it targets an essential process, is effective against a collection 
of clinical isolates, and is not a substrate for efflux pumps21. The data presented here indicate that MAC13243 
makes E. coli more permeable when used at sub-lethal concentrations. We therefore speculated that the permea-
ble phenotype was caused by partial inhibition of LolA. To explore this possibility we mimicked partial inhibition 
by reducing the intra-cellular levels of LolA using the CRISPR interference (CRISPRi) technology35. When we 
induced expression of a single gRNA (sgRNA) specific for lolA together with the nuclease-deficient Cas9 (dCas9) 
we observed that cell growth was perturbed compared to control cells expressing an sgRNA for the non-essential 
gene lacZ (encoding ß–galactosidase) (Fig. 5a). This outcome was expected as lolA is essential for viability36 
whereas lacZ is not37. When we monitored the permeability of LolA-depleted cells using the NPN assay, we 
observed that they were more permeable than LacZ-depleted cells (Fig. 5b). We could not confirm that LolA lev-
els were depleted, as we did not have antisera to LolA. But we were able to show that outer membrane lipoproteins 
and ß-barrel proteins were partially retained at the inner membrane (Fig. 5c). In the control, we observed that 
an inner membrane protein (PpiD) was enriched in the inner membrane fraction, whereas an outer membrane 
protein (OmpA), and two lipoproteins (BamB, LptE) were enriched in the outer membrane fraction. However in 
LolA-depleted cells the outer membrane proteins were enriched in the inner membrane, which is consistent with 
our hypothesis that LolA levels were partially depleted by CRISPRi. The genetic reconstruction therefore demon-
strates the principle that partial depletion of LolA is sufficient to make E. coli more permeable.
Discussion
Antibiotic resistance is a major public health threat38–40. And although new antibiotics are urgently needed the 
antibiotic discovery pipelines are virtually empty, particularly for gram-negative bacteria41–43. Given this situation, 
it has been widely acknowledged that we should find better ways to use the antibiotics that we already have at our 
disposal40,44–46. With this philosophy in mind we set out to identify lead molecules that could make gram-negative 
bacteria more permeable, and more susceptible to large-scaffold antibiotics. Large-scaffold antibiotics are valua-
ble community resources that were originally discovered as natural products, and decades of synthetic tailoring 
has created generations of molecules with improved characteristics41. These antibiotics are already in the public 
domain, but they are not used to treat gram-negative infections because they cannot efficiently cross the outer 
membrane8,10,47–50. We suggest that they represent an untapped community resource that could be repurposed 
to treat gram-negative infections, if there were approaches to increase the permeability of the outer membrane.
Figure 4. MAC13243 makes E. coli more susceptible to some large-scaffold antibiotics. (a) E. coli MC4100 cells 
were exposed to 10 μM MAC13234, or large-scaffold antibiotics (½ MIC), or both. Cells were grown in LB for 
18 h at 37 °C and cell growth was determined by measuring the optical density (OD600). MICs were determined 
to be 512 μg mL−1 for vancomycin, 16 μg mL−1 for rifampicin, 256 μg mL−1 for erythromycin and 64 μg mL−1 for 
novobiocin. (b) MAC13243 functions synergistically with some large-scaffold antibiotics. Heat plots showing 
growth inhibition of E. coli MC4100 in the presence of MAC13243 and vancomycin, rifampicin, erythromycin 
or novobiocin (in M9 media). Percentage of growth is illustrated with different colours where black represents 
100% growth and red 0% growth. These data were used to calculate FICIs (see text for details). MICs were 
determined to be 256 μg mL−1 for MAC13243, 128 μg mL−1 for vancomycin, 8 μg mL−1 for rifampicin, 
256 μg mL−1 for erythromycin and 1024 μg mL−1 for novobiocin.
www.nature.com/scientificreports/
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Our study identified MAC13243, which has previously been shown to be an inhibitor of the essential peri-
plasmic chaperone LolA21. The previous work had shown that MAC13243 had antibacterial activity against 
gram-negative bacteria, and the authors suggested that it was a promising lead molecule. We too observed that 
MAC13243 had antibacterial activity (MIC ranging from 8 to 256 mg mL−1, depending on whether the cells were 
grown in LB or M9 minimal media). However a subsequent study noted that MAC13243 degrades in aqueous 
solution, casting doubt over its usefulness51.
In this study we show for the first time, that sub-inhibitory concentrations of MAC13243 can be used to 
make E. coli more permeable. In our experiments we observed that E. coli cells were more permeable to the 
fluorescent dye NPN, as well as large-scaffold antibiotics from four different antibiotic classes when treated 
with sub-inhibitory concentrations of MAC13243. The fact that cells were more permeable to NPN than 
colistin-treated cells suggests that MAC13243 is effective at inducing a permeable phenotype. A molecular reason 
for the permeable phenotype is speculated on in Fig. 6. We reason that a sub-lethal concentration of MAC13243 
results in partial inhibition of the LolA chaperone. Since LolA traffics proteins from the inner to the outer mem-
brane, partial inhibition will result in retention of lipoproteins at the inner membrane. E. coli encodes around 90 
different lipoproteins, many of which have no known function13. However three outer membrane lipoproteins 
are directly involved in outer membrane biogenesis and are essential for cell viability: LolB inserts lipoproteins 
into the outer membrane13, BamD inserts ß-barrel proteins into the outer membrane1 and LptE inserts LPS mol-
ecules into the outer membrane52. Thus partial inhibition of LolA can simultaneously affect the function of three 
proteins that are essential for maintaining the integrity of the outer membrane. Indeed, when we depleted the 
intracellular levels of LolA using CRISPRi, we observed that LptE was partially retained at the inner membrane, 
and that cells were more permeable to NPN. We were unable to determine if LolA-depletion was sufficient to 
Figure 5. Partial depletion of LolA increases the permeability of the outer membrane. (a) CRISPRi-mediated 
knockdown of LolA or LacZ in E. coli MC4100. Expression of dCas9 together with the respective lacZ sgRNA 
(control) or lolA sgRNA was induced at t = 90 min with 200 ng mL−1 aTC and growth was monitored by 
measuring optical density (OD600). (b) An aliquot of cells was taken 4 h after induction and permeability was 
monitored by the NPN uptake assay. All data (mean +/− S.D.) are from four experiments. ****p < 0.0001 
(unpaired t-test.). (c) Depletion of LolA levels by CRISPRi affects the trafficking of both lipoproteins and 
ß-barrel proteins to the outer membrane. Inner and outer membrane fractions were purified from both LacZ-
depleted cells (control) and LolA-depleted cells using a sucrose gradient. The proteins from each fraction were 
then separated by SDS-PAGE, transferred to a nitrocellulose membrane and probed with anti-sera to an inner 
membrane protein (PpiD), an outer membrane protein (OmpA), and two outer membrane lipoproteins (BamB 
and LptE). Full-length blots are shown in Supplementary Figure 4.
www.nature.com/scientificreports/
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cause susceptibility to large-scaffold antibiotics, since the CRISPRi system requires two plasmids with different 
antibiotic selection markers. Nevertheless the experiment indicated that LolA-depletion was sufficient to increase 
the permeability of E. coli.
Although the high throughput screen carried out in this study is unique, the molecule we identified 
(MAC13243) is similar to an antibiotic potentiator identified in a previous study23. In the aforementioned study 
the authors screened 30,000 compounds for their ability to potentiate the activity of novobiocin (also a large 
scaffold antibiotic). They identified A22 or S-(4-dichlorobenzyl)isothiourea, an inhibitor of the actin-like protein 
MreB. A22 is structurally similar to the thiourea moiety of MAC13243, which is liberated in aqueous solution 
as MAC13243 is hydrolysed51 (see S-(4-chlorobenzyl)isothiourea in Fig. 7). MAC13243, its degradation product 
S-(4-chlorobenzyl)isothiourea and A22 are of the same molecular class and it is therefore not surprising that they 
can all bind to LolA21,51 and cause the outer membrane to be more permeable to NPN (Fig. 3; Supplementary 
Figure 3). However it is surprising that two independent studies have identified essentially the same molecule as a 
potentiator of large-scaffold antibiotics, since there are literally hundreds of target proteins in E. coli. For example, 
E. coli is more susceptible to vancomycin when one of 60 different proteins is inactivated12.
Can MAC13243 be used as a potentiator of large-scaffold antibiotics? Whilst we observed that a sub-inhibitory 
concentration of MAC13243 worked synergistically with large-scaffold antibiotics like novobiocin and erythro-
mycin in lab strains of E. coli, it did not work synergistically with larger scaffolds such as rifampicin and vanco-
mycin. Furthermore it did not work synergistically with any of the tested antibiotics in clinical isolates (although 
we did observe increased permeability). Thus we suggest that MAC13243 will need to be chemically modified if it 
is to be used clinically as a potentiator of large-scaffold antibiotics. However it may have a number of immediate 
uses in biotechnology, such as improving the uptake of large labelling dyes or precursor compounds used for the 
production of complex chemicals in cell factories.
Methods
Bacterial strains, chemicals and media. The E. coli strain MC4100 (F−, [araD139]B/r, Δ(argF-lac)169, 
λ−, e14-, flhD5301, Δ(fruK-yeiR)725(fruA25), relA1, rpsL150(strR), rbsR22, Δ(fimB-fimE)632(::IS1), deoC1)) was 
used for all experiments unless otherwise stated. The E. coli O139 and O141 strains were obtained from Klas 
Udekwu (Stockholm University, Sweden). The BW25113 ΔwaaG and lptD4213 strains were obtained from Göran 
Widmalm (Stockholm University, Sweden) and Daniel Kahne (Harvard Medical School, USA), respectively. 
Figure 6. A model depicting how MAC13243 could affect the permeability of the outer membrane in E. coli. 
Lipoprotein precursors are synthesised on cytosolic ribosomes, then trafficked to the periplasm through either 
the Sec or Tat translocons. In the periplasm the N-terminal cysteine residue is acylated and then cleaved in 
successive reactions by Lgt, LspA and Lnt (not shown). Left panel, the mature lipoprotein is bound by the ABC 
transporter complex LolCDE then released to the periplasmic chaperone LolA. The LolA-lipoprotein complex 
is trafficked to the outer membrane where it binds to the LolB receptor and transfers the lipoprotein cargo. LolB 
then inserts the lipoprotein into the outer membrane. Note that some lipoproteins have a Lol avoidance signal 
and they are retained in the inner membrane. See13 for more details. Right panel, a sub-lethal concentration 
of MAC13243 (step 1) results in partial inhibition of LolA (step 2). This results in the partial retention of 
outer membrane lipoproteins at the inner membrane (step 3). Some of these mis-targeted lipoproteins are 
directly involved in outer membrane biogenesis, such as LolB (insertion of lipoproteins13), BamB (insertion of 
ß-barrel proteins1) and LptE (insertion of LPS molecules52). Thus partial depletion of LolA can directly affect 
the biogenesis of the key components of the outer membrane, which weakens the membrane and results in 
increased permeability (step 4). The increased permeability in cells treated with MAC13243 can be exploited to 
increase the uptake of NPN and large-scaffold antibiotics (step 5).
www.nature.com/scientificreports/
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Strains were either grown in LB broth (Amresco, Stockholm) or M9 minimal medium containing 1x M9 minimal 
salts (BD Difco, Stockholm, Sweden), 0.4% D-glucose (VWR Chemicals, Stockholm, Sweden), 2 mM MgSO4 
(Sigma Aldrich, Stockholm, Sweden) and 0.1 mM CaCl2 (Sigma Aldrich, Stockholm, Sweden). Antibiotics and 
other chemical compounds were purchased from the following manufacturers: Vancomycin, rifampicin, eryth-
romycin, novobiocin and 1-(N-phenylamino)naphthalene (NPN) from Sigma Aldrich (Stockholm, Sweden); 
MAC13243 from MedChem Express (Stockholm, Sweden); 5-Floxuridine and Streptozotocin from Cayman 
Chemical (Michigan, USA); Carbadox from Alfa Aesar (Karlsruhe, Germany) and anhydrotetracycline (aTc) 
from VWR (Stockholm, Sweden).
The High-Throughput Screen. The first part of the primary screen consisted of 17,500 compounds from 
a diverse set of small molecules (ChemBridge) screened at a final concentration of 12.5 µM. The second part 
consisted of 10,500 compounds from the CBCS primary screening set (Chemical Biology Consortium Sweden) 
screened at a final concentration of 10 µM. The compounds were Echo® spotted (Labcyte) directly into 96-well 
Nunclon™Δ surface plates (Thermo Fisher Scientific, Stockholm, Sweden). A colony of E. coli MC4100 was inoc-
ulated into LB broth and incubated overnight at 37 °C with shaking at 200 rpm. The overnight culture was diluted 
to OD600 = 0.01 and supplemented with 150 μg mL−1 vancomycin (100 µg mL−1 for the first 17,500 compounds). 
A 200 μL aliquot of diluted bacteria was then added to each well of the pre-spotted 96-well plates. The plates 
were incubated for 5 h at 37 °C without shaking and the OD600 were recorded with the Synergy H4 plate reader 
(BioTek). The growth control consisted of 200 μL diluted bacteria with 200 nl of DMSO. The sterility control con-
sisted of 200 μL sterile growth media.
Validation experiments. Selected small molecules were further analysed in dose-response experiments 
(with and without vancomycin). Briefly, diluted bacteria were prepared as described in the previous section. A 
200 μL aliquot of diluted bacteria was either supplemented with or without 150 μg mL−1 vancomycin and added 
to a 96-well Nunclon™Δ surface plate and then mixed with two-fold serial dilutions of each small molecule at 
concentrations ranging from 0 - 20 μM. The plates were incubated for 5 h at 37 °C without shaking and the OD600 
was recorded.
Figure 7. MAC13243 is degraded in solution. (a) MAC13243 is hydrolysed into one molecule 
of 3,4-dimethoxyphenethylamine, two molecules of formaldehyde and one molecule of S-(4-chlorobenzyl)
isothiourea. At neutral pH the t1/2 is 13 h. Both MAC13243 and the degradation product S-(4-chlorobenzyl)
isothiourea bind to LolA21,51. (b) An analogue of the degradation product, called A22 or S-(4-dichlorobenzyl)
isothiourea, also binds LolA. Curiously this compound is a known inhibitor of the cytoskeletal protein MreB51. 
Figure adapted from51, with permission from the publisher.
www.nature.com/scientificreports/
9SCieNTiFiC REPORTS | 7: 17629  | DOI:10.1038/s41598-017-17772-6
Minimal Inhibitory Concentration (MIC) determination. The MIC of each antibiotic and small mol-
ecule was determined prior to the outer membrane integrity assays. A single colony of E. coli MC4100 was inoc-
ulated into either 5 mL LB broth or M9 minimal medium and incubated overnight at 37 °C and 200 rpm. The 
overnight culture was diluted with sterile growth medium to an OD600 = 0.0005. 198 μL of diluted cells per well 
were added to a 96-well Nunclon™Δ surface plate and mixed with 2 μL of two-fold serial dilutions of antibiotic 
or small molecule with a final concentration ranging from 0 to 2048 μg mL−1. After an 18 h incubation at 37 °C 
without shaking, the samples were transferred to a 96-well Costar plate (VWR, Stockholm, Sweden) and the 
OD600 was recorded in a SpectraMax M2e Microplate Reader (Molecular Devices, CA, USA). The growth control 
consisted of 198 μL diluted culture and 2 μL of the corresponding solvent. The sterility control consisted of 200 μL 
sterile growth medium and served as a background control. The MIC was defined as bacterial growth that was 
reduced by more than 90% compared to the growth control.
Outer membrane integrity assays. The permeability of the outer membrane was analysed by using the 
NPN uptake assay as previously described29. Briefly, a colony of E. coli MC4100 was inoculated into 5 mL of M9 
media and incubated overnight at 37 °C with shaking at 200 rpm. The overnight culture was diluted with sterile 
M9 medium to an OD600 = 0.1 and incubated in a 96-well Nunclon™Δ surface plate without shaking at 37 °C until 
the culture reached an OD600 = 0.5. The cells were harvested by centrifugation (15,000 x g for 2 min), washed twice 
with assay buffer (5 mM HEPES, 5 mM glucose, pH 7.2) and resuspended in assay buffer to a final OD600 = 1. 
Then, 100 μL of washed cells and 100 μL of assay buffer containing 20 μM NPN were mixed together and added 
to a 96-well optical-bottom black plate (Thermo Fisher Scientific, Stockholm, Sweden). Either 2 μL of a chemical 
compound, or the corresponding solvent, was added to each well and fluorescence was immediately monitored in 
a SpectraMax Gemini EM microplate reader (Molecular devices, CA, USA) at an excitation wavelength of 350 nm 
and emission wavelength of 420 nm for 10 min at 30 sec intervals. For each time point, the NPN uptake was cal-
culated using equation (1) where Fobs is the observed fluorescence at a given chemical compound concentration, 
Fcontrol is the fluorescence of NPN with E. coli cells in the presence of the corresponding solvent and FB is the fluo-
rescence of NPN in the absence of E. coli cells. Data collected over a 10 minutes was averaged.
= − − −NPN uptake F F F F( ) ( ) (1)obs B control B
Susceptibility testing with large-scaffold antibiotics. A single colony of E. coli MC4100 was inocu-
lated into 5 mL of LB broth and incubated overnight at 37 °C with shaking at 200 rpm. The overnight culture was 
diluted with sterile LB medium to an OD600 = 0.0005. A 196 μL aliquot of diluted cells was added to each well of a 
96-well Nunclon™Δ surface plate and mixed with 2 μL of MAC13243 (final concentration of 10 μM) and/or 2 μL 
of either vancomycin (f.c. 128 μg mL−1), rifampicin (f.c. 8 μg mL−1), erythromycin (f.c. 128 μg mL−1) or novobi-
ocin (f.c. 32 μg mL−1). The growth control contained 198 μL of diluted bacteria and 2 μL of DMSO. The sterility 
control contained 200 μL sterile growth medium and served as a background control. After an 18 h incubation at 
37 °C without shaking, the OD600 was recorded as mentioned previously.
Checkerboard dilution assay. Checkerboard dilution assays were performed to investigate if a given 
combination of MAC13243 and antibiotic worked synergistically. The protocol was adapted from23. Briefly, an 
overnight culture of E. coli MC4100 was diluted with sterile M9 medium to an OD600 = 0.0005. A 196 μL aliquot 
of diluted culture was added to each well of a 96-well Nunclon™Δ surface plate and mixed with either 2 μL of 
MAC13243 and/or 2 μL of antibiotic with concentrations ranging from 0 to 1024 μg mL−1. After an 18 h incuba-
tion at 37 °C without shaking, the OD600 was measured as described previously. The growth control consisted of 
196 μL of diluted culture, 2 μL of DMSO and 2 μL of either H2O or EtOH. To evaluate if any given combination 
was synergistic, equation (2) was used to calculate the FIC (fractional inhibitory concentration) index where 
FICA is the MIC of drug A in combination with drug B divided by the MIC of drug A alone and FICB is the MIC 
of drug B in combination with drug A divided by the MIC of drug B alone. The combinations were deemed syn-
ergistic (FICI ≤ 0.5), additive (FICI > 0.5 to 1), indifferent (FICI > 1 to < 2) or antagonistic (FICI ≥ 2), as defined 
by community guidelines33.
= + = +FIC index FIC FIC MIC
MIC
MIC
MIC
( ) ( )
(2)A B
AB
A
BA
B
CRISPRi. The sgRNA-expressing plasmids were constructed according to53. In short, a protospacer adjacent 
motif (PAM) sequence (5′-NGG-′3) and adjacent 20 nucleotides were selected on the non-template strand for 
lacZ and lolA (as close to the start codon as possible). Each sgRNA construct was transformed together with the 
dCas9-expression vector into E. coli MC4100 and selected on LB agar supplemented with 34 μg mL−1 chloram-
phenicol and 25 μg mL−1 kanamycin. A colony of each transformed strain was inoculated into 5 mL of LB medium 
containing the appropriate antibiotics and grown overnight at 37 °C with shaking at 200 rpm. The cultures were 
then diluted to OD600 = 0.01, supplemented with fresh antibiotics and 5 mL of diluted cultures were added into 
a 24-well plate (GE Healthcare, Uppsala, Sweden). Cells were incubated at 37 °C with shaking at 200 rpm and 
expression of dCas9 and the corresponding sgRNA (sgRNA-LacZ or sgRNA-LolA) was induced with 200 ng 
mL−1 aTc at OD600 = 0.1.
Membrane fractionation and western blot analysis. A single colony of E. coli MC4100 transformed 
with the dCas9-expression vector and the corresponding sgRNA (sgRNA-LacZ or sgRNA-LolA) was inoculated 
into 20 ml LB medium (containing the appropriate antibiotics) and incubated overnight at 37 °C with shaking at 
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200 rpm. The overnight cultures were diluted with sterile LB to an OD600 = 0.01 in a final volume of 1 L. Incubation 
was continued under the same conditions for 2 h and expression of dCas9 and the corresponding sgRNA was 
induced with 200 ng mL−1 aTc. After an additional 5 h incubation under the same conditions, cells were harvested 
from 2 L of culture, by centrifugation for 20 min at 5000 × g at 4 °C. Harvested cells were resuspended in 1 × PBS 
and subsequently broken by passing three times through an Emulsiflex-C3 (Avestin, Mannheim, Germany). 
Unbroken cells were pelleted by centrifugation for 20 min at 8000 × g at 4 °C. The membrane fraction was pelleted 
from the supernatant by ultracentrifugation for 1 h at 270,000 × g at 4 °C. Membrane fractions were resuspended 
in 1 ml PBS, placed on top of a three-step sucrose gradient (0.77 M, 1.44 M and 2.02 M sucrose) and separated 
by ultracentrifugation for 16 h at 230,000 × g at 4 °C as described previously54. The inner and outer membrane 
fractions (IM + OM) were collected, then proteins were separated by 12% SDS-PAGE and blotted onto a nitrocel-
lulose membrane using a semi-dry blotting device (Bio-Rad, Stockholm, Sweden). The nitrocellulose membranes 
were decorated with antisera, and detection was carried out using the ECL system (Thermo Scientific, Stockholm, 
Sweden) and a LAS-1000 CCD camera (Fujifilm).
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